NRXP compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

NRXPNRX Pharmaceuticals, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

NRXPNRX Pharmaceuticals, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NRXP1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±34.2%▲+4.89%×0.14

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedNRXP realized, solidLLY realized, hatchedOne scale, both sides: full bar = 35%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

NRXPNRX Pharmaceuticals, Inc.

2.25· pre 2.32· delayed

Mkt cap$94.0MRevenue$6,000Q2 FY26Revenue—

LLYELI Lilly & Co

1,407.25· pre 1,422.00· delayed

Pre-marketNov 4 '26delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Pre-marketNov 4 '26delayed

NRXPNRX Pharmaceuticals, Inc.

LLYELI Lilly & Co

2.25pre 2.32delayed

Price

1,407.25pre 1,422.00delayed

$94.0M

Mkt cap

$1.3T

Q2 FY26$6,000

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

NRXP2.25vsLLY1,407.25Pre-marketNov 4 '26delayed